164788-90-3Relevant articles and documents
Substituted kynurenines and process for their preparation
-
, (2008/06/13)
The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT). The prese
Derivatives of kynurenine as inhibitors of rat brain kynurenine aminotransferase
Varasi,Della Torre,Heidempergher,Pevarello,Speciale,Guidetti,Wells,Schwarcz
, p. 11 - 21 (2007/10/03)
The structural requirements of the catalytic site of kynurenine aminotransferase (KAT), the enzyme responsible for the conversion of L-kynurenine (KYN) to kynurenic acid (KYNA), were examined using analogs and derivatives of KYN. KYNA production from KYN was monitored in rat brain homogenates and brain tissue slices. Modification of KYN's acylalanine side chain or its ring amino group resulted in compounds which did not substantially affect KYNA synthesis. Ring chlorination in positions 3, 4, 5 and 6 yielded KYN analogs which interfered with KYNA production. L-5-Cl-KYN was the most active of the chlorinated kynurenines, and one of the most potent of several other 5-substituted kynurenines. L-5-Cl-KYN was an excellent substrate of KAT, yielding 6-Cl-KYNA. Finally, in kinetic studies, L-5-Cl-KYN (K(i) = 5.4 μM) was found to have an approximately five times higher affinity to the enzyme than the natural substrate KYN (K(m) = 28 μM).
